Peanut allergy therapy proves effective during phase 3 clinical trial
March 29, 2018
Wesley Burks, MD, was a principal investigator on the phase 3 PALISADE trial to determine the efficacy of the AR101 oral immunotherapy developed by Aimmune Therapeutics for people allergic to peanuts.